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Translational relevance 
Despite impressive advances with systemic therapies on patients with metastatic 
melanoma, patients with melanoma brain metastases (MBM) still have a poor overall 
survival. Identifying and overcoming MBM-specific resistance mechanisms is therefore a 
major aim in the search for successful treatments. Recent studies have implicated a 
fundamental role of the PI3K-AKT signaling pathway in survival and growth of melanoma 
cells in the brain microenvironment. Our studies show that inhibition of the PI3K-AKT 
pathway leads to growth arrest and induction of apoptosis in brain metastatic melanoma 
cells in vitro and in vivo. This provides a strong rationale for targeting this pathway in 
melanoma patients with brain metastases and will be investigated in a recently initiated 
clinical trial.  
 
Abstract 
Purpose: Great advances have recently been made in treating patients with metastatic 
melanoma. However, existing therapies are less effective on cerebral than extracerebral 
metastases. This highlights the potential role of the brain environment on tumor 
progression and drug resistance and underlines the need for “brain-specific” therapies. We 
previously showed that the PI3K-AKT survival pathway is hyperactivated in brain but not 
extracerebral melanoma metastases and that astrocyte-conditioned medium activates AKT 
in melanoma cells in vitro. We therefore tested the PI3K inhibitor buparlisib as an 
antitumor agent for melanoma brain metastases.  
Experimental Design and Results: Buparlisib inhibited AKT activity, decreased proliferation 
and induced apoptosis in metastatic melanoma cell lines and short-term brain melanoma 
cells, irrespective of their BRAF and NRAS mutation status. Additionally, buparlisib 
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inhibited hyperactivated AKT and induced apoptosis in melanoma cells that were 
stimulated with astrocyte-conditioned medium. The growth of tumors induced by injecting 
human BRAF- and NRAS-mutant metastatic melanoma cells into the brain of mice was 
significantly inhibited by buparlisib.  
Conclusions: These results emphasize the value of targeting the PI3K pathway as a 
strategy to develop drugs for melanoma brain metastases. 
 
Introduction 
Melanoma is one of the most common tumors that metastasizes to the brain. Up to 75% of 
patients with stage IV melanoma develop brain metastases (1). Brain metastases are 
associated with significant morbidity and very poor prognosis, showing a median overall 
survival of 3-6 months (2). Patients with a good performance status, controlled 
extracerebral metastases, and brain metastases that can be managed by neurosurgery or 
radiosurgery, have a better prognosis, including long-term survival. The approval of 
effective systemic drugs has revolutionized the treatment of metastatic melanoma. BRAF 
inhibitors have demonstrated efficacy in fighting active BRAFV600 mutated melanoma 
brain metastases. In a phase II trial, the BRAF inhibitor dabrafenib led to an intracranial 
objective response rate (ORR) of 31-39%, a median progression-free survival (PFS) of 16-
17 weeks and a median overall survival (OS) of 31-33 weeks in BRAFV600E-mutated 
melanoma patients with asymptomatic brain metastases (3). Another phase II study with 
the BRAF inhibitor vemurafenib in patients with BRAFV600-mutated melanoma and 
asymptomatic and symptomatic brain metastases displayed an intracranial ORR of 18-
20%, a median PFS of 16-18 weeks and a median OS of 28 weeks (4). However, the 
benefit for these patients is limited by the short response duration and lack of complete 
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durable responses. The cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody, ipilimumab, 
has also shown activity in asymptomatic melanoma brain metastases, with an intracranial 
ORR of 16%, a median PFS of 6 weeks and a median OS of 30 weeks (5). However, the 
same survival benefit was not evident for patients with symptomatic melanoma brain 
metastases that are dependent on a high dose of steroids (5). Thus, there is an urgent 
need for alternative treatments for melanoma patients with brain metastases.  
Emerging data on the molecular characteristics of melanoma brain metastases suggest 
that brain metastases show significant differences compared to extracerebral metastases 
and primary tumors that may contribute to intracerebral therapy resistance. Whereas 
treatment with the BRAF inhibitor vemurafenib resulted in partial or complete remission of 
extracerebral metastases, brain metastases appeared or progressed (6, 7). 
Immunohistochemical analyses of brain metastases and matched extracerebral 
metastases revealed the PI3K-AKT signaling pathway but not the RAF-MEK-ERK (MAPK) 
signaling pathway to be hyperactivated in the brain (6, 7). While levels of ERK, pERK, and 
AKT appeared to be identical, levels of pAKT were significantly increased in brain 
metastases. This clinical difference is very significant, because ERK, pERK, AKT, and 
pAKT expressions were shown to be identical in monolayer cultures derived from 
melanoma brain and extracerebral metastases. Additionally, melanoma cells cultured in 
astrocyte-conditioned medium again showed higher AKT activation and invasiveness than 
when cultured in fibroblast-conditioned medium. 
This suggests that brain-derived factors may hyperactivate the AKT survival pathway, 
promoting invasiveness and drug resistance of melanoma cells in the brain. Thus, 
inhibition of PI3K-AKT signaling with PI3K inhibitors such as buparlisib may help defeat 
melanoma brain metastases. 
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Buparlisib is a potent pan-class I PI3K inhibitor that selectively targets the catalytic 
isoforms of class IA (p110α, p110β, p110δ) and class IB (p110γ) PI3Ks. Buparlisib inhibits 
proliferation and induces apoptosis in various tumor cell lines (8, 9). Furthermore, it inhibits 
the growth of human tumors in xenograft mouse models in a well-tolerated manner and 
very efficiently penetrates the blood-brain barrier (8-10). Buparlisib reduced glioblastoma 
tumor spread in orthotopic xenograft models (11). A phase I clinical trial using buparlisib 
on a variety of solid tumors showed good disease control and tolerable toxicity (12). 
Additionally, a clear clinical benefit was demonstrated in breast cancer patients treated 
with buparlisib alone (13). Recently, phase II and phase III clinical trials have been 
extended to lung cancer, head and neck cancer and glioblastoma. Several studies suggest 
that the antitumor effects are enhanced when buparlisib is combined with other anticancer 
agents. For instance, combination of buparlisib with fulvestrant in endocrine-resistant 
HR+/HER2- breast cancer significantly improved PFS, ORR and CBR (clinical benefit 
rate), particularly in patients with mutated PIK3CA (phosphatidylinositol-4,5-bisphosphate 
3-kinase catalytic subunit alpha) (14). 
Taken together, the favorable properties of the PI3K inhibitor buparlisib in terms of 
potency, selectivity, brain penetrance, and the reported clinical benefit in other cancers 
make it a good candidate for treating patients with melanoma brain metastases. We 
therefore wanted to investigate the antitumor activity of buparlisib in melanoma brain 
metastases in vitro and in vivo. 
 
Materials and Methods 
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Isolation and culture of human cells 
We used human metastatic melanoma cell lines, which were BRAF-mutant (WM3734, 
451Lu, A375, SKMel19), NRAS-mutant (SKMel147, WM1346, WM1366, MelJuso) or 
BRAF/NRAS wt (ZueMel1H). The cell lines were kindly provided by M. Herlyn, K. Smalley 
and R. Dummer or purchased from the American Type Culture Collection. In addition, we 
used the patient derived brain tumor cell lines M10 (BRAF-mutant), TueMel32H (NRAS-
mutant), ZueMel2H, TueMel20H and TueMel41H, respectively. The cells were cultured in 
RPMI 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin. 
Melanoma cell lines, cells isolated from excised brain or extracerebral melanoma 
metastases, and fibroblasts were isolated and cultured as described previously (15). All 
patients provided written consent. The use of human tissues in this study was approved by 
the medical ethical committee of the Universities of Dresden, Zürich and Tübingen and 
performed in accordance with the Declaration of Helsinki Principles. 
 
Signaling pathway inhibitors and treatments  
For blockade of the RAF-MEK-ERK pathway, the BRAF inhibitor encorafenib (Novartis) 
and the MEK inhibitor binimetinib (Novartis) were employed. For inhibition of the PI3K-AKT 
pathway, the PI3K inhibitor buparlisib (Novartis) was used. The inhibitors were added at 
concentrations ranging from 0.3 to 10 µM to the culture medium of cells with 50-70% 
confluency. Controls were incubated with dimethylsulfoxide (DMSO) alone. 
 
Western blot analyses 
After 1-24 h incubation with the inhibitors, the cells were lysed directly in the dish for 30 
min on ice with buffer containing 10 mM Tris pH 7.5, 0.5% Triton X-100, 5 mM EDTA, 0.1 
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µM phenylmethanesulphonylfluoride, 10 µM Pepstatin A, 10 µM Leupeptin, 25 µM 
aprotinin, 20 mM NaF, 1 mM pyrophosphate, 1 mM orthovanadate. Lysates were cleared 
by centrifugation at 13,000 g for 30 min and 15– 60 µg protein was subjected to SDS-
PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. Proteins were 
detected with Cell Signaling primary antibodies (AKT #9272, pAKTSer473 #4060, ERK 
#9102, pERKThr202/Tyr204 #4376 and β-Actin #4970) and HRP-conjugated secondary 
antibodies (Amersham), and membranes were exposed to X-ray film (Eastman Kodak). All 
images were scanned and cropped in the Adobe Photoshop editing software. 
 
Growth assay (MUH assay) 
Cells seeded in quadruplicates in 96-well plates were treated with the various inhibitors for 
72 h, washed twice with PBS and then incubated with 100 µl of a solution containing 100 
µg/ml 4-methylumbelliferyl-heptanoate (MUH) in PBS for 1 h at 37°C. The absolute 
fluorescence intensity at λex of 355 nm and λem of 460 nm was measured using a 
Fluoroskan II device (Labsystems). The intensity of fluorescence corresponds to the 
number of viable cells.  
 
Cell-cycle analysis 
Cells seeded in triplicates in 6-well plates were treated with buparlisib for 72 h. Floating 
and adherent cells were harvested, washed with PBS and fixed in ice-cold 70% ethanol 
overnight. After washing twice with cold PBS, cells were stained with 500 µl propidium 
iodide solution (propidium iodide 40 µg/ml and RNase 100 µg/ml in PBS) for 20 min at 
4°C. The cell cycle was analyzed using flow cytometry and FACSDiva software (BD 
Biosciences).  
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Immunohistochemistry 
For immunohistochemical analysis, human tumor tissue was fixed in 4% formalin, 
embedded in paraffin and stained with H&E, HMB45 (Dako #M0634) or pAKTSer473 
(CellSignaling #4060). Bound antibodies were detected using UltraView Universal Alkaline 
Phosphatase Red Detection kits from Ventana (Tucson).  
 
Immunofluorescent labelling 
Human tumor tissue embedded in paraffin was prepared as described above. Sections 
were blocked for 5 min with Ultra V Block solution (Thermo Scientific) and then incubated 
overnight with antibodies against cleaved PARP (CellSignaling #5625) and MIB1 (Ki67, 
DAKO #M7240). Sections were washed with PBS and incubated for 1 h with a Cy3-
coupled donkey-anti-mouse secondary antibody or a Cy5-coupled donkey-anti-rabbit 
antibody (Dianova, Hamburg, Germany). Nuclei were detected with YOPRO (Molecular 
Probes, Leiden Netherlands). Samples were analyzed using a Leica TCS SP confocal 
microscope (Leica, Wetzlar, Germany). 
 
In vivo mouse model 
Stereotactic inoculation of melanoma cells into the brain of nude mice 
In a stereotactic surgical procedure 150,000 human melanoma cells (WM3734 or 
SKMel147) were injected into the right striatum of 8-week-old female CD1nu/nu mice 
(Charles River Laboratories). All animals were housed under standardized environmental 
conditions (20 ± 1°C room temperature, 50 ± 10% relative humidity, and 12 h light-dark 
phases) with free access to food and water ad libitum. To achieve sufficient analgesia the 
mice were injected i.p. with Meditomidin/Midazolam/Fentanyl (0.5/5/0.05 mg/kg body 
weight). The anesthetized animals were positioned in the stereotactic apparatus by fixing 
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the head in the ear bars. After opening the skin and the skull, the cells were injected with a 
Hamilton syringe (150,000 cells in 3 µl) using a stereotactic holder to insert the syringe into 
the mouse brains. Afterwards the wound was sutured and the mice were given carprofen 
(5 mg/kg body weight, twice daily, for 2-3 days s.c.) postoperatively. 
All experiments were performed according to the animal use and care protocol (§8 
21.06.2012) of the German Animal Protection Law and approved by the 
Regierungspräsidium Tübingen. 
 
Evaluation of the tumor volume  
The tumor volume was evaluated by MRI (BRAF-mutant tumors: Icon (1T-MRI; Multi slice 
multi echo (MSME) Sequence, repetition time (TR) = 2931 ms, echo time (TE) = 60 ms, 
188 x 88 matrix, 22 x 45 mm field of view, slice thickness (ST) = 0.75 mm) and NRAS-
mutant tumors: ClinScan (7T-MRI; Turbo spin echo (TSE) Sequence, TR = 3000 ms, TE = 
205 ms, 256 x 161 matrix, 35 x 57 mm field of view, ST = 0.22 mm from Bruker BioSpin 
GmbH) and analyzed using the software Inveon Research Workplace (Siemens Preclinical 
Solutions). The first measurement was performed 15-16 days post inoculation. After the 
start of the therapy at day 20 post inoculation the animals were monitored twice weekly. All 
mice were sacrificed at the onset of neurological symptoms, at 20% loss in weight or at the 
latest 34 days after inoculation. The brains were excised and fixed in formalin for 
immunohistochemical analysis.  
For mean value analyses, only the mice with a tumor volume ≥ 3 mm3 when treatment was 
commenced were included. For all tumors the absolute tumor volume (Fig. 5) as well as 
the relative tumor volume (Fig. S6), normalized by the volume at treatment induction, was 
analyzed. Exponential fitting was applied on the tumor growth curves of the absolute tumor 
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volume. Kaplan-Meier-plots were generated on the basis of animals reaching the endpoint 
criteria of 20% loss in weight.   
 
Treatment of animals 
Buparlisib was administered daily (30 mg/kg body weight) on 14 consecutive days (8, 9), 
starting 20 days after the tumor inoculation, when the tumors were clearly visible in the 
MRI scans.  
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism version 5.01 (GraphPad Prism 
Software Inc.). The differences between the two groups were compared using the 
nonparametric Mann-Whitney Test (95% CI). P-values <0.05 were considered statistically 
significant. N-values represent the number of independent experiments unless stated 
otherwise. 
Statistical analysis of the in vivo MRI growth data was performed using JMP® Statistical 
Discovery version 11.0.0. The difference between the treated and the sham groups for 
multiple time points was analyzed using a Tukey-HSD posthoc test.       
 
Results 
The PI3K inhibitor buparlisib inhibits AKT phosphorylation and cell growth in 
metastatic melanoma cell lines with different mutation signatures 
We and others previously showed that the PI3K-AKT pathway is hyperactivated in 
melanoma brain metastases. Moreover, melanoma cells stimulated with astrocyte-
conditioned medium showed increased AKT activation and invasiveness. Based on these 
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results, we investigated whether the PI3K inhibitor buparlisib could be implemented as an 
antitumor agent for melanoma brain metastases.  
To verify that buparlisib inhibits the PI3K-AKT pathway, the phosphorylation status of AKT 
was investigated in three metastatic melanoma cell lines carrying different mutation 
signatures (BRAFV600E: WM3734; NRASQ61R: SKMel147; BRAF/NRASwt: ZueMel1H). 
Buparlisib effectively inhibited the phosphorylation of AKT in a dose-dependent manner in 
all of the cell lines independent of the mutation status (Fig. 1A). Consistenly, buparlisib 
inhibited growth of all three cell lines by 60-70%, as measured by the fluorimetric 4-
methylumbelliferyl heptanoate (MUH) assay (Fig. 1B).  
Similar results were obtained with six other BRAF- or NRAS-mutated metastatic melanoma 
cell lines (Supplementary Fig. S1 and S2), confirming that buparlisib effectively inhibits 
AKT phosphorylation and proliferation of a variety of melanoma cell lines in vitro. 
 
Growth inhibition is enhanced when the PI3K inhibitor buparlisib is combined with a 
MEK inhibitor 
In order to test whether the PI3K inhibitor buparlisib can augment the effect of specific 
MEK and BRAF inhibitors, the three different metastatic melanoma cell lines were tested 
for growth inhibition after treatment with each of these inhibitors alone or in combination.  
The MEK inhibitor binimetinib alone inhibited proliferation by 50-60% in the BRAF- and 
NRAS-mutated, and by 20% in the BRAF/NRAS wildtype metastatic melanoma cells, while 
co-treatment with buparlisib yielded significantly higher growth-inhibition (80%) 
(Supplementary Fig. S3A). 
Since treatment of BRAFV600E metastatic melanoma cells with increasing concentrations 
of the BRAF inhibitor encorafenib alone already inhibited cell growth by 80%, co-treatment 
with buparlisib did not yield additional improvement (Supplementary Fig. S3B).  
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Furthermore, AKT phosphorylation was inhibited by buparlisib, with or without encorafenib 
or binimetinib, starting within 1 h after stimulation (Supplementary Fig. S3C). Inhibition of 
AKT phosphorylation was still effective after 24 h. As expected, pERK levels were inhibited 
by binimetinib and encorafenib, but remained unaffected by buparlisib at 1 h and 24 h after 
treatment.  
In summary, combining MEK and PI3K inhibitors inhibits growth more effectively than 
specific MEK inhibitors alone, regardless of the mutation status of the target cell. In all 
cases growth inhibition coincided with siginificant reduction of pAKT as well as pERK 
levels. In contrast, the PI3K inhibitor did not augment the efficacy of the BRAF inhibitor in 
the BRAF-mutated cell line.  
 
The PI3K inhibitor buparlisib induces apoptosis in metastatic melanoma cell lines 
To investigate whether growth inhibition induced by buparlisib also coincides with induction 
of cell death, cell cycle analysis was performed for all three mutation-specific melanoma 
cell lines. Buparlisib treatment caused a cell-cycle arrest in the G2/M phase in the BRAF-
mutated cell line, and additionally a 20-50% increase of cells in the sub-G1 phase 
(apoptotic cells) in all cell lines tested (Fig. 2 A and B). Similar results were obtained with 
six other BRAF- and NRAS-mutant metastatic melanoma cell lines, confirming the ability of 
buparlisib to drive a variety of melanoma cell lines into apoptotic cell death 
(Supplementary Fig. S1C and S2C). 
 
The PI3K inhibitor buparlisib inhibits proliferation and induces apoptosis in short-
term brain melanoma cells 
To add more in vivo relevance to the growth inhibitory and cell death inducing effects of 
buparlisib two melanoma cell lines (BRAF- und NRAS-mutated) directly isolated from 
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excised brain metastases of patients were investigated. In accordance with our previous 
observations, activated AKT was significantly decreased after buparlisib treatment as 
shown by Western Blot analysis (Fig. 3A). Buparlisib also inhibited growth by up to 70% in 
these as well as three other short-term brain melanoma cell lines (Fig. 3B and 
Supplementary Fig. S4). Furthermore, buparlisib caused G2/M arrest and a 15% increase 
in apoptosis in the BRAF-mutated cell line, and a 40% increase in apoptosis in the NRAS-
mutated cell line (Fig. 3C and 3D). 
In contrast, non-tumor-derived cells of human skin such as fibroblasts stayed largely 
resistant to buparlisib, with growth being inhibited by only 40% at the highest buparlisib 
concentration and no increased apoptosis (Supplementary Fig. S5A). Together, these 
findings strongly imply that buparlisib selectively acts on tumor cells. 
  
The PI3K inhibitor buparlisib inhibits AKT activation and induces apoptosis in 
metastatic melanoma cell lines stimulated with astrocyte-conditioned medium 
In order to evaluate buparlisib for the treatment of brain metastases, we mimicked the 
brain environment in vitro by culturing WM3734 brain-metastatic melanoma cells in 
astrocyte-conditioned medium. As seen before, astrocyte- but not fibroblast-conditioned 
medium increased the pAKT levels in WM3734 cells, which were completely inhibited by 
addition of 1 µM buparlisib (Fig. 4A). Moreover, the PI3K inhibitor buparlisib induced 
apoptosis in approximately 20% of melanoma cells (Fig. 4B and 4C), indicating that 
buparlisib can successfully combat the changes being induced by the brain 
microenvironment. 
 
The PI3K inhibitor buparlisib inhibits growth of BRAF- and NRAS-mutant melanoma 
in the brain of nude mice 
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The encouraging results of buparlisib antitumor activity on melanoma cells placed in an 
artificial brain microenvironment, prompted us to assess its effects on intracranial tumor 
growth using an in vivo mouse model of orthotopically transplanted human BRAF-mutant 
and NRAS-mutant melanoma brain metastases.  
Excitingly, mice treated with the PI3K inhibitor buparlisib showed no further tumor growth, 
while mice treated only with the vehicle developed rapidly growing tumors in the brain, in 
both, the BRAF- and the NRAS-mutated tumors (Fig. 5A). Significant differences in relative 
tumor volumes (Supplementary Fig. S6A) as well as in absolute tumor volumes (Fig. 5B) 
between the buparlisib and sham treated mice were observed 7 days after treatment onset 
(day 27 post inoculation) for the BRAF-mutant cells and 6 days after treatment induction 
(day 26 post inoculation) for the NRAS-mutant cells. For both cell lines exponential fitting 
was applied to the growth curves of all tumors, verifying the inhibition of the exponential 
growth pattern of all tumors in the buparlisib treated animals against the sham treated 
controls (Supplementary Fig. S6B). After 34 days a Kaplan-Meier-plot showed moderate 
survival for both the sham and the treatment group in the BRAF-mutant tumor mice but 
dramatically improved survival in the treatment group for the NRAS-mutant tumors (Fig. 
5C). 
The 7T TSE MRI data of the NRAS-mutated tumors allowed us to identify T2 hyperintense 
regions indicative of hemorrhages and cysts as well as peritumoral edema (Supplementary 
Fig. S6C). Peritumoral edema was mild and not seen in all animals. Interestingly, there 
was a remarkable increase of T2 hyperintense regions in the therapy group, with multifocal 
intratumoral areas of liquid indicative of hemorrhages or cysts. In the sham group most 
tumors appeared relatively homogeneous and with distinctively fewer T2 hyperintense 
areas. 
PI3K inhibition in melanoma brain metastases 
 
18
H&E staining of untreated and treated BRAF- and NRAS-mutant tumors confirmed what 
was seen in the MRI (Supplementary Fig. S7A). Intratumoral bleeding was seen in both 
treatment groups, but was considerably higher in the buparlisib-treated group 
(Supplementary Fig. S7B). Necrosis was detected in all untreated NRAS-mutant tumors, 
highlighting the aggressiveness of the NRAS-mutant tumors (Supplementary Fig. S7C). 
However, there were also areas of tumor regression, in which the tumor shrank and was 
replaced by water-filled pseudo-cysts (Supplementary Fig. S7D). Buparlisib caused a 
substantial increase of these pseudo-cysts in the treated NRAS-mutant tumors, with M12 
exhibiting up to 70% of tumor regression.  
The effectiveness of buparlisib could also be visualized in immunohistochemical stainings 
for pAKT and immunofluorescence stainings for Ki67 (proliferation marker) and cleaved 
PARP (apoptosis marker) (Supplementary Fig. S8). Although buparlisib could not induce 
sufficient apoptosis to achieve clearance of the tumors (Supplementary Fig. S8A and C), it 
almost completely inhibited proliferation and tumor growth (Supplementary Fig. S8B and 
D). As expected, AKT activation was completely prevented by buparlisib (Supplementary 
Fig. 8E).  
In summary, the PI3K inhibitor buparlisib inhibited growth of BRAF-mutant, and even more 
effectively of NRAS-mutant melanoma cells in the brain of mice, providing evidence for its 
potent antitumor activity on melanoma brain metastases in vivo.  
 
DISCUSSION 
 
Recently, impressive novel treatment strategies have been developed for patients with 
metastatic melanoma, particularly through inhibiting the RAF-MEK-ERK signaling pathway 
and by immunotherapy. Although these systemic therapies have been remarkably 
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successful in fighting metastatic melanoma, patients frequently develop brain metastases 
during these therapies. So far, little is known about how melanoma brain metastases 
evade existing therapies. Investigating matched samples from melanoma patients with 
both cerebral and extracerebral metastases, the PI3K-AKT signaling pathway was found to 
be upregulated in cerebral compared to extracerebral metastases (6, 16). This prompted 
us to investigate the antitumor activity of the PI3K inhibitor buparlisib in melanoma brain 
metastases in vitro and in vivo.  
We show here that buparlisib prevented AKT activation and cell growth of a variety of 
metastatic melanoma cell lines in vitro. In addition, it caused an arrest in the G2/M phase 
and induced apoptosis to varying degrees in these cell lines.  
Our in vivo experiments demonstrated robust inhibition of AKT activation as well as 
proliferation of human melanoma cells implanted into the brain of mice, indicating that 
buparlisib crosses the blood-brain barrier, as suggested by earlier xenograft experiments 
(8, 9). The inhibitory effect of buparlisib prevailed irrespective of the BRAF or NRAS 
mutation status. In particular in mice with NRAS-mutated brain tumors treatment with 
buparlisib provided a survival benefit compared to sham treatment. Although the tumors 
were smaller in the BRAF-mutated group, mice of both, the sham and the treatment group 
showed rapid weight loss, reaching the endpoint of 20% loss in weight faster than the 
NRAS-mutated group. Evaluation of the tumor sections suggested a fundamental 
difference between the NRAS- and BRAF-mutated tumors. Although the NRAS-mutated 
tumors seemed to be more aggressive, the inhibitory effect of buparlisib was much more 
prominent in these tumors compared to BRAF-mutated tumors. As RAS but not RAF can 
signal through the PI3K-AKT pathway, NRAS-mutated tumors are probably more sensitive 
to PI3K pathway inhibition than BRAF-mutated tumors. However, more extensive 
experiments would be needed to further investigate this prediction. 
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In our in vitro experiments, the combination of the PI3K inhibitor buparlisib with a MEK or 
BRAF inhibitor led to robust inhibition of AKT and ERK activation. Furthermore, combining 
the PI3K inhibitor buparlisib with the MEK inhibitor binimetinib inhibited the growth of the 
melanoma cell lines significantly better than the PI3K or MEK inhibitor alone, irrespective 
of the mutation status. These data are in line with recent in vivo studies. In a BRAF 
inhibitor resistant patient-derived xenograft model, tumor growth was significantly better 
controlled by buparlisib in combination with encorafenib plus binimetinib compared to 
buparlisib or encorafenib plus binimetinib alone (17). Similar results were obtained when 
the PI3K inhibitor buparlisib was combined with the ERK inhibitor VX-11e (17). 
In our BRAF-mutated brain metastatic melanoma cells the PI3K inhibitor buparlisib did not 
enhance the potent growth inhibition by the BRAF inhibitor encorafenib. However, in a pilot 
study, combinations of buparlisib and encorafenib improved the survival of mice with 
intracranial BRAF-mutated tumors compared to encorafenib alone (16). Accordingly, 
similar findings were obtained by using another BRAF inhibitor (PLX4720) and pan-PI3K 
inhibitor (PX-866) (18).  
These data suggest that combining the PI3K inhibitor buparlisib with a BRAF/MEK inhibitor 
may prolong response duration and survival in melanoma patients with BRAF-mutated 
brain metastases. However, a preliminary study of eight cases in which buparlisib was 
combined with the BRAF inhibitor vemurafenib was not as successful, as half the patients 
developed dose limiting toxicities such as myalgia, DRESS syndrome and febrile 
neutropenia, and only one of the eight patients showed a mixed response to the treatment 
(19). Given that in breast cancer clinical trials combination treatment with buparlisib and 
the estrogen-receptor antagonist fulvestrant significantly improved the overall survival in 
the absence of severe side effects (14), further clinical trials of buparlisib or other PI3K 
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inhibitors in combination with RAF/MEK inhibitors will be required to determine the actual 
clinical benefit. 
Since buparlisib inhibits class I PI3 kinases with similar potency, the present data do not 
resolve which PI3K isoforms within the PI3K-AKT signaling cascade are being activated by 
the brain microenvironment. Isoform selective inhibitors are currently being clinically 
investigated, and could offer an alternative strategy if a pan-PI3K inhibitor such as 
buparlisib is not tolerated in combination with MAP kinase pathway inhibitors. 
 
Our data on buparlisib inhibiting AKT activation and decreasing growth of human 
melanoma cells in the brain of mice highlights the importance of the PI3K-AKT pathway in 
the survival and growth of brain metastatic melanoma cells and is nicely in line with 
previous reports. Multidimensional molecular profiling of matched cerebral and 
extracerebral melanoma metastases found no differences in hotspot mutations, copy-
number variations, mRNA and protein expression, but detected increased expression of 
several activation-specific protein markers of the PI3K-AKT pathway in brain metastases 
(16). Furthermore, in a retrospective analysis, complete loss of the phosphatase PTEN, 
which inhibits PI3K, correlated with more rapid brain metastasis formation and decreased 
overall survival in stage IIIB/C melanoma patients with BRAFV600 mutations (20). A 
recent study suggested a functional crosstalk between PI3K-AKT signaling and PLEKHA5 
to exist in melanoma brain metastases (21). PLEKHA5 was overexpressed in 
cerebrotropic A375 melanoma cells, and its knockdown stopped the cells from proliferating 
and migrating across the blood-brain barrier in vitro. PLEKHA5 possesses a pleckstrin 
homology domain that facilitates recruitment to the plasma membrane and binding to 
phosphoinositides such as PIP3 (22). As PIP3 is generated by the PI3-kinase, a PI3K 
inhibitor such as buparlisib might inhibit PLEKHA5 membrane association and its function. 
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When staining the untreated versus treated NRAS- and BRAF-mutated tumors for 
PLEKHA5, we found that PLEKHA5 was significantly decreased in the buparlisib-treated 
tumors (Supplementary Fig. S9). One may speculate that after loss of its membrane 
association, PLEKHA5 is targeted for proteasomal degradation. As PLEKHA5 expression 
correlates with the early onset of melanoma brain metastases (21), PI3K inhibition may be 
a new strategy to affect melanoma brain metastasis formation via targeting PLEKHA5. 
 
We observed that mimicking the brain environment in vitro by stimulating metastatic 
melanoma cells with astrocyte-conditioned medium increased the pAKT levels. Buparlisib 
completely prevented this increase and induced apoptosis in these cells. These results 
illustrate how the brain microenvironment activates the PI3K-AKT pathway, potentially 
allowing brain metastases to resist therapy. Several studies have demonstrated 
interactions between astrocytes and tumor cells including melanoma cells. The interaction 
with astrocytes upregulates multiple genes in melanoma cells, including several survival 
genes that increase their resistance to cytotoxic drugs (23). It has been demonstrated 
recently that astrocytes epigenetically repress expression of the negative regulator of PI3K 
signaling, PTEN, in metastatic tumor cells (24). Another experimental study showed that 
brain-metastatic melanoma cells acquire neuron-like characteristics (25), which may 
intensify their interactions with normal brain cells and promote survival and growth (25). 
This brain-specific signature overlaps with previous data showing significant transcript 
differences between melanoma cells harvested from the brain compared to other 
metastatic sites (26). Moreover, interactions between astrocytes and melanoma cells 
seem to be reciprocal, as melanoma cells can reprogram astrocytes to express IL-23 (27). 
This inflammatory cytokine in turn causes the melanoma cells to secrete the matrix 
metalloproteinase MMP2, thereby enhancing their invasiveness (27).  
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In conclusion, our data provide evidence that hyperactivation of the PI3K-AKT pathway is 
a prominent feature of melanoma brain metastases. Even though the molecular 
mechanisms underlying PI3K-AKT hyperactivation remain to be determined, our data 
provide a strong rationale for targeting this pathway in melanoma patients with brain 
metastases. Combinations of PI3K inhibitors with BRAF or MEK inhibitors may significantly 
increase antitumor activity and prolong survival. A phase II trial of buparlisib in patients 
with stage IV melanoma and brain metastases has been initiated (NCT02452294). The 
results will further increase our knowledge about the potential of buparlisib for treating 
melanoma brain metastases.  
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Figure legends  
Figure 1: The PI3K inhibitor buparlisib inhibits AKT phosphorylation and cell growth 
in metastatic melanoma cell lines 
(A) WM3734 (BRAF-mutant), SKMel147 (NRAS-mutant) and ZueMel1H (BRAF/NRASwt) 
metastatic melanoma cell lines were treated with increasing concentrations of the PI3K 
inhibitor buparlisib for 6 h and were subjected to Western Blot analysis of AKT and pAKT. 
PI3K inhibition in melanoma brain metastases 
 
28
β-Actin was detected as a loading control. Western Blot is representative of three 
independent experiments. Western Blots of 8 other BRAF- or NRAS-mutant cell lines are 
shown in Fig. 3, S1 and S2. (B) Metastatic melanoma cells were treated with buparlisib for 
72 h and subjected to a growth inhibition assay (MUH assay). The percentage of growth 
inhibition was compared to DMSO-treated controls. Error bars represent SD of three 
independent experiments. Growth inhibition assays of 11 other BRAF- or NRAS-mutant 
cell lines are shown in Fig. 3, S1, S2 and S4. 
 
Figure 2: The PI3K inhibitor buparlisib induces apoptosis in metastatic melanoma 
cell lines  
WM3734 (BRAF-mutant), SKMel147 (NRAS-mutant) and ZueMel1H (BRAF/NRASwt) 
metastatic melanoma cell lines were treated with increasing concentrations of the PI3K 
inhibitor buparlisib for 72 h and subjected to cell cycle analysis by flow cytometry. 
Histograms in (A) are representative of triplicate experiments. The percentage of cells in 
<G1, G1, S and G2/M phase was quantified and displayed in a stacked bar graph (B). 
Error bars represent SD of triplicate experiments. Cell-cycle analysis of 8 other BRAF- or 
NRAS-mutant cell lines is shown in Fig. 3, S1 and S2. 
 
Figure 3: The PI3K inhibitor buparlisib inhibits AKT phosphorylation and cell growth 
and induces cell cycle arrest and apoptosis in short-term brain melanoma cell lines 
(A) Brain derived melanoma cells were treated with increasing concentrations of the PI3K 
inhibitor buparlisib for 6-12 h and were subjected to Western Blot analysis of AKT and 
pAKT. β-Actin was detected as a loading control. Western Blot is representative of three 
independent experiments. (B) Brain melanoma cells were treated with buparlisib for 72 h 
and then subjected to a growth inhibition assay (MUH assay). The percentage of growth 
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inhibition was compared to DMSO-treated controls. Error bars represent SD of three 
independent experiments. (C and D) Brain melanoma cells were treated with buparlisib for 
72 h and then subjected to cell cycle analysis by flow cytometry. Histograms in (C) are 
representative of triplicate (TueMel32H) or three independent (M10) experiments. The 
percentage of cells in <G1, G1, S and G2/M phase was quantified and displayed in a 
stacked bar graph (D). Error bars represent SD. 
 
Figure 4: The PI3K inhibitor buparlisib inhibits AKT activation and induces 
apoptosis in metastatic melanoma cell lines stimulated with astrocyte-conditioned 
medium 
The WM3734 (BRAF-mutant) metastatic melanoma cell line was cultured in RPMI, 
astrocyte- (ACM) and fibroblast-conditioned medium (FCM) without FCS and treated with 
or without 1 µM PI3K inhibitor buparlisib for 30 h. (A) Samples were harvested for Western 
Blot and analyzed for AKT and pAKT. β-Actin was detected as a loading control. Western 
Blot is representative of three independent experiments. (B and C) Samples were 
subjected to cell-cycle analysis by flow cytometry. Histograms in (B) are from three 
independent experiments. The percentage of cells in <G1, G1, S and G2/M phase was 
quantified and displayed in a stacked bar graph (C). Error bars represent SD of three 
independent experiments. 
 
Figure 5: The PI3K inhibitor buparlisib inhibits growth of metastatic melanoma in the 
brain of nude mice 
Representative MRI data of injected WM3734 (BRAF-mutant) human melanoma brain 
metastasis under buparlisib or sham treatment (A). MRI was performed 16, 20, 23, 27 and 
30 days after inoculation. On day 20 post inoculation (p.i.) the treatment was started. 
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Buparlisib induced stable disease, compared to rapid tumor growth in the sham-treated 
animals for both BRAF-mutant (WM3734) and NRAS-mutant (SKMel147) brain metastasis, 
shown by mean values ± SD of the absolute tumor volume (B). For mean value analyses 
the mice with secure tumor indication at day 19-20 were included (tumor volume ≥ 3 mm3; 
n = 8/8 in the BRAF-mutated group; n = 5/5 in the NRAS-mutated group); even if not 
visible at day 15 in the NRAS-mutated group (n = 3/3 at day 15). Significant differences 
were reached 7 and 6 days after treatment induction for the BRAF- and NRAS-mutant 
tumors respectively, as determined by Tuckey-HSD posthoc tests. Kaplan-Meier-plots 
showed moderate survival for both, the treatment and sham group in BRAF-mutant tumors 
but dramatically improved survival of the treatment group in NRAS-mutant tumors (C). 
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